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3eart Disease in
iabetes—Resist the Beginnings
he study by Fang et al. (1), together with the accompanying
ditorial by Picano (2), draws attention to early functional changes
f the heart in diabetes. It is tempting to take the story one step
urther: to consider the consequences of changes in energy sub-
trate supply to the heart. Diabetes is as much a disorder of
ysregulated fatty acid metabolism as it is a disorder of dysregu-
ated glucose metabolism (3), and, in the blood of diabetic patients,
atty acid levels are elevated along with glucose levels. We have
ound substantial changes in the metabolic gene expression profile
f hearts from diabetic animals before the onset of functional
bnormalities (4,5). This is one end of the spectrum. At the other
nd of the spectrum, the transcriptional profile of diabetic patients
ith heart failure reveals a severe downregulation of the myocyte
nhancer factor-2 (MEF2C) and its target genes (6) contributing
o more severe contractile dysfunction. We proposed that meta-
olic remodeling in diabetes precedes, causes, and sustains the
unctional and structural remodeling of the heart (7,8). Conse-
uently, early detection and correction of the metabolic abnormal-
ties should also prevent the heart’s functional decline later on.
hen used early enough, new pharmacological agents directed at
etabolic targets may prevent a significant amount of cardiovas-
ular disease (9). The Romans used to have a term for this:
rincipiis obsta—“Resist the beginnings.”
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EPLY
greatly appreciate the thoughtful comment of Drs. Taegtmeyer
nd Razeghi. In my editorial to the study by Fang et al. (1), I
escribed an “echocardiographic cascade” in the natural history of
iabetic cardiomyopathy, with subtle, preclinical, possibly revers-
ble changes in inotropic reserve, coronary flow-reserve, and
ltrasonic tissue structure preceding more advanced, profound, and
ess, if at all, reversible changes in resting regional or global systolic
unction (2). No doubt that echocardiographic signs—however
arly—are only the consequences of the altered upstream metabolic
nd/or genetic condition. I proposed metabolic changes (with
onenzymatic glycation), according to what seemed to me (a
etabolically and simple minded clinical cardiologist, I must
dmit) the most likely and proven explanation to date. There is
ittle surprise to learn that knowledgeable experts propose a more
ophisticated and elegant explanation: a genetically regulated
isturbance in fatty acid metabolism that is present in both early
nd in more advanced phases of diabetic cardiomyopathy.
I do not know whether this is the only truth, but most likely it
s part of it. In diabetic cardiomyopathy, disturbances in glucose
etabolism coexist with alterations in fatty acid metabolism.
urther upstream, there could be oxidative somatic DNA damage,
hich may co-generate and amplify the onset of clinical compli-
ations (3). Each of these components (genetic, metabolic, inflam-
atory, etc.) is part of a multifaceted and—at least for the
linician—still elusive pathogenetic entity. The quest for the holy
rail of the metabolic source of diabetic cardiomyopathy cascade is
till ongoing. Only by drying the (metabolic and/or genetic) source
an we hope to halt the cardiomyopathy cascade that eventually
eads the diabetic patient to heart failure and cardiac death.
owever, we are far from achieving this goal. The Romans used to
ave a term for this: Acta est fabula: “The game has just started.”
ugenio Picano, MD, PhD, FESC
NR
nstitute of Clinical Physiology
ia Moruzzi, 1
6124 Pisa
taly
icano@ifc.cnr.it
doi:10.1016/j.jacc.2003.11.004
EFERENCES
. Fang ZY, Najos-Valencia O, Leano R, Marwick TH. Patients with
early diabetic heart disease demonstrate a normal myocardial response to
dobutamine. J Am Coll Cardiol 2003;42:446–53.
. Picano E. Diabetic cardiomyopathy: the importance of being earliest.
J Am Coll Cardiol 2003;42:454–7.
. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in
diabetes mellitus. Lancet 1996;347:444–5.
